Avalo Therapeutics: Deep Track reports 5.81% stake

Avalo Therapeutics, Inc. Schedule 13G: Deep Track Capital, Deep Track Biotechnology Master Fund and David Kroin report beneficial ownership of 3,055,027 shares of Avalo Common Stock, representing 5.81% of the class as reported.

Rhea-AI Filing Summary

Avalo Therapeutics, Inc. Schedule 13G: Deep Track Capital, Deep Track Biotechnology Master Fund and David Kroin report beneficial ownership of 3,055,027 shares of Avalo Common Stock, representing 5.81% of the class as reported.

The filing states the ownership figures are calculated using 52,565,572 shares outstanding as of May 8, 2026, per the issuer's 10-Q. The statement is a joint filing by the named reporting persons and identifies Deep Track Capital, LP as the relevant entity for which Kroin may be considered a control person.

Insights

Institutional Ownership Analyst

Deep Track reports a 5.81% beneficial stake in Avalo using an issuer-supplied outstanding share count.

The filing lists 3,055,027 shares beneficially owned and shows shared voting and dispositive power for the reporting entities. Ownership is presented as a joint filing with attribution to Deep Track Capital, LP as the primary entity.

Timing and mechanics of any potential sales or acquisitions are not disclosed in the excerpt; subsequent SEC filings would state any trading activity or amendments.

Key Figures

Beneficially owned shares: 3,055,027 shares Percent of class: 5.81% Shares outstanding used: 52,565,572 shares +1 more

4 metrics

Beneficially owned shares 3,055,027 shares reported beneficial ownership as of May 29, 2026

Percent of class 5.81% percentage of common stock calculated using May 8, 2026 outstanding count

Shares outstanding used 52,565,572 shares shares outstanding as of May 8, 2026 per issuer 10-Q

CUSIP 05338F306 Avalo Therapeutics Common Stock CUSIP

Key Terms

Schedule 13G, Beneficial ownership, Shared dispositive power, Joint filing

4 terms

Schedule 13G regulatory

"Item 1. (a) Name of issuer: Avalo Therapeutics, Inc."

A Schedule 13G is a formal document that investors file with the government when they acquire a large ownership stake in a company, usually for investment purposes rather than control. It helps keep the public informed about who owns significant parts of a company's shares, which can influence how the company is managed and how investors make decisions. Filing this schedule is important for transparency and understanding the ownership landscape of publicly traded companies.

Beneficial ownership financial

"Item 4. (a) Amount beneficially owned: 3,055,027"

Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.

Shared dispositive power financial

"Item 4. (iv) Shared power to dispose: 3,055,027"

Joint filing regulatory

"JOINT FILING STATEMENT PURSUANT TO RULE 13d-1(k)"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What stake does Deep Track report in Avalo Therapeutics (AVTX)?

Deep Track reports beneficial ownership of 3,055,027 shares, equal to 5.81% of the outstanding common stock. The percentage is calculated using 52,565,572 shares outstanding as of May 8, 2026 per the issuer's 10-Q.

Which entities filed the Schedule 13G reporting this position in AVTX?

The Schedule 13G is filed jointly by Deep Track Capital, LP, Deep Track Biotechnology Master Fund, Ltd., and David Kroin, with Deep Track Capital, LP identified as the relevant entity for control-person attribution.

Does the filing show who can vote or sell the reported shares?

The filing shows shared voting power and shared dispositive power of 3,055,027 shares for the reporting persons and 0 sole voting or dispositive power. Specific transfer or sale intentions are not disclosed in the excerpt.

What outstanding share count did the filers use to calculate their percentage?

The percentage is calculated using 52,565,572 shares outstanding as of May 8, 2026, cited from Avalo's 10-Q filed May 13, 2026. That outstanding share number is the denominator for the 5.81% figure.

When was the Schedule 13G signed and who signed it?

The document is dated May 29, 2026 and signed by David Kroin in multiple capacities: Managing Member of the general partner of the investment adviser, Director, and individually as a reporting person.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/29/2026 - 04:37 PM Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

Avalo Therapeutics, Inc.

(Name of Issuer)

Common Stock, $0.001 par value

(Title of Class of Securities)

05338F306

(CUSIP Number)

05/22/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 05338F306

1

Names of Reporting Persons

Deep Track Capital, LP

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 3,055,027.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 3,055,027.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

3,055,027.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.81 %

12

Type of Reporting Person (See Instructions)

IA, OO

SCHEDULE 13G

CUSIP Number(s): 05338F306

1

Names of Reporting Persons

Deep Track Biotechnology Master Fund, Ltd.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

CAYMAN ISLANDS

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 3,055,027.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 3,055,027.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

3,055,027.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.81 %

12

Type of Reporting Person (See Instructions)

CO

SCHEDULE 13G

CUSIP Number(s): 05338F306

1

Names of Reporting Persons

David Kroin

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 3,055,027.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 3,055,027.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

3,055,027.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.81 %

12

Type of Reporting Person (See Instructions)

HC, IN

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Avalo Therapeutics, Inc.
(b)	Address of issuer's principal executive offices: 1500 Liberty Ridge Drive, Suite 321, Wayne, PA 19087
Item 2.
(a)	Name of person filing: (i) Deep Track Capital, LP (ii) Deep Track Biotechnology Master Fund, Ltd. (iii) David Kroin
(b)	Address or principal business office or, if none, residence: (i) 200 Greenwich Ave, 3rd Floor, Greenwich, CT 06830 (ii) c/o Walkers Corporate Limited, 190 Elgin Ave, George Town, KY1-9001, Cayman Islands (iii) c/o Deep Track Capital, LP, 200 Greenwich Ave, 3rd Floor, Greenwich, CT 06830
(c)	Citizenship: (i) Delaware (ii) Cayman Islands (iii) United States
(d)	Title of class of securities: Common Stock, $0.001 par value
(e)	CUSIP Number(s): 05338F306
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 3,055,027
(b)	Percent of class: 5.81%
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 0
	(ii) Shared power to vote or to direct the vote: 3,055,027
	(iii) Sole power to dispose or to direct the disposition of: 0
	(iv) Shared power to dispose or to direct the disposition of: 3,055,027
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary. Deep Track Capital, LP is the relevant entity for which David Kroin may be considered a control person.
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Deep Track Capital, LP

Signature:	/s/ David Kroin
Name/Title:	David Kroin, Managing Member of the General Partner of the Investment Adviser
Date:	05/29/2026

Deep Track Biotechnology Master Fund, Ltd.

Signature:	/s/ David Kroin
Name/Title:	David Kroin, Director
Date:	05/29/2026

David Kroin

Signature:	/s/ David Kroin
Name/Title:	David Kroin
Date:	05/29/2026

Exhibit Information

Item 4: Information with respect to the Reporting Persons' ownership of the Common Stock as of May 29, 2026, is incorporated by reference to items (5) - (9) and (11) of the cover page of the respective Reporting Person. The amount beneficially owned by each Reporting Person is calculated using 52,565,572 shares outstanding as of May 8, 2026, according to the issuer's 10-Q filed with the SEC on May 13, 2026. JOINT FILING STATEMENT PURSUANT TO RULE 13d-1(k) The undersigned acknowledge and agree that the foregoing statement on SCHEDULE 13G, is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on SCHEDULE 13G, shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate. Dated: May 29, 2026 Deep Track Capital, LP By: /s/ David Kroin David Kroin, Managing Member of the General Partner of the Investment Adviser Deep Track Biotechnology Master Fund, Ltd. By: /s/ David Kroin David Kroin, Director David Kroin By: /s/ David Kroin David Kroin